MetaCap

BioLineRx Ltd. ADR (BLRX)

NASDAQ: BLRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.9639-0.0861 (-8.20%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BLRX stock chart

Technical analysis

Key statistics

All statistics
52-week range
0.78 – 3.95
Day range
0.78 – 1.10
Volume / Avg
38.77K / 23.43K
Beta
—
Next earnings
Nov 23, 2026

52-week range

$0.78$3.95

BLRX stock today

BioLineRx (BLRX) closed at $0.9639 on Nov 20, down 8.20% (-$0.0861), versus the S&P 500's 3.70% decline. At this level, BLRX sits near the bottom of its 52-week range of $0.78 to $3.95: 75.6% below the high, set on May 29, 2026 and 23.6% above the low. BLRX is down 65.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 70.3%.

BioLineRx has posted a net loss over the last twelve months (EPS of $0.00), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Nov 23 before the market opens; analysts expect EPS of -$0.38.

Summary generated from market data by MetaCap's automated system. Methodology

About BioLineRx

Company profile

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions.

Industry
Biotechnology: Pharmaceutical Preparations
Headquarters
Hevel Modi'in
Employees
20

Financial highlights

Full financials

In fiscal 2025, BioLineRx generated $1.2 million in revenue, down 95.9% from fiscal 2024, the first decline in the 11 years shown. BioLineRx reported a net loss of $2.0 million, compared with a loss of $9.2 million a year earlier. Gross margin was 80.5% (up from 68.0%) and operating margin -871.8%.

BioLineRx annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.18M$28.94M$4.80M$0$0
Growth-95.92%+502.92%———
Net income$-2.03M$-9.22M$-60.61M$-24.95M$-27.05M
EPS (diluted)$0.00$-0.01$-0.06$-0.03$-0.04

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$22.00+2182.39%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $18.00High $26.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Nov 23, 2026
EPS estimate
$-0.38

BLRX news

All BLRX news

BioLineRx peers

Health Care sector
BLRX peer companies
CompanyPrice% ChgMarket capCompare
PULMPulmatrix Inc.1.27-10.56%$4.64Mvs BLRX
SNGXSoligenix Inc.0.2201-8.29%$5.14Mvs BLRX
PCSAProcessa Pharmaceuticals Inc.1.56-7.69%$4.37Mvs BLRX
CANFCan-Fite Biopharma Ltd ADR1.44-2.34%$4.35Mvs BLRX
CNSPCNS Pharmaceuticals Inc.3.56-12.75%$5.25Mvs BLRX
UPCUniverse Pharmaceuticals Inc. Class A1.08-20.59%$5.43Mvs BLRX
TOVXTheriva Biologics Inc.0.12-6.25%$5.51Mvs BLRX
SCNXScienture Holdings Inc.2.28-6.45%$4.07Mvs BLRX

Indexes, lists and sector

BioLineRx stock FAQ

What is BioLineRx's stock price today?

BLRX last traded at $0.9639 as of Nov 20, 4:00 PM EST, down 8.20% on the day. Prices are delayed at least 15 minutes.

Does BioLineRx pay a dividend?

No. BioLineRx does not currently pay a regular cash dividend.

When is BioLineRx's next earnings date?

BioLineRx is expected to report earnings on Monday, November 23, 2026. Analysts expect EPS of $-0.38.

Has BLRX ever split its stock?

Yes. The most recent BLRX stock split was a 1-for-40 split on Jan 30, 2025, one of 2 splits on record.

What is the BLRX 52-week high?

The 52-week high for BLRX is $3.95 and the 52-week low is $0.78. The stock is currently 75.6% below its high.

Compare BLRX